GSK · Categories · M&A
GSK - Mergers and acquisitions
GSK plc (GSK) mergers and acquisitions - real-time wire coverage filtered to M&A only.
Recent M&A for GSK
- GSK and CureVac to Restructure Collaboration into New Licensing AgreementGSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinationsCureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replacedLONDON, UK, TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 3, 2024 / GSK plc (NYSE:GSK) and CureVac N.V. (NASDAQ:CVAC) today announced they have restructured their existing collaboration into a new licensing agreement, allowing each company to prioritize investment and focus their respective mRNA
- Stock-exchange announcement - For media and investors only - GSK completes acquisition of BELLUS HealthLONDON, June 28, 2023 /CNW/ - GSK plc (LSE: GSK) (NYSE:GSK) and BELLUS Health Inc. (TSX:BLU) NASDAQ: BLU) today announced GSK has completed the acquisition of BELLUS, a biopharmaceutical company working to better the lives of patients suffering from refractory chronic cough (RCC), by way of a plan of arrangement in accordance with Section 192 of the Canada Business Corporations Act (the "Arrangement"). The Arrangement was approved by BELLUS' shareholders on 16 June 2023. As previously announced, the acquisition of BELLUS includes camlipixant, a potential best-in-class and highly selective P2X3 antagonist currently in phase III development for the first-line treatment of adult patients with R
- ViiV Healthcare to present new long-term findings from its innovative 2-drug and long-acting HIV medicines portfolio at CROI 2022Data reinforce ViiV Healthcare's leadership and commitment to developing ground-breaking medicines for HIV treatment and prevention ViiV Healthcare, the global specialist HIV company majority-owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. (Pfizer) and Shionogi Limited (Shionogi) as shareholders, today announced the presentation of company and investigator sponsored abstracts from its industry-leading HIV treatment and prevention portfolio of approved long-acting medicines and 2-drug regimens (2DRs) at the Conference on Retroviruses and Opportunistic Infections (CROI 2022), being held virtually 12-16 February. Key data presentations will include: Data demonstrating further evidence
- ViiV Healthcare announces US FDA approval of Apretude (cabotegravir extended-release injectable suspension), the first and only long-acting injectable option for HIV preventionGiven as few as six times per year and demonstrated superior efficacy to a daily oral PrEP option (FTC/TDF tablets) in reducing the risk of HIV acquisition Approved in the US for use in adults and adolescents weighing at least 35 kg who are at risk of sexually acquiring HIV, including men who have sex with men as well as women and transgender women who have sex with men ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. (Pfizer) and Shionogi Limited (Shionogi) as shareholders, today announced that the US Food and Drug Administration (FDA) approved Apretude, the first and only long-acting injectable pre-exposure prophylaxis (